Search clinical trials for: Shingles vaccine

Total 9984 results

Shenzhen Shenxin Biotechnology Co., Ltd

Not yet recruiting

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Herpes Zoster
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Not yet recruiting

A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years

Herpes Zoster

Australia
Pfizer

Recruiting

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Shingles | Human | Herpes Zoster Infection

United States
Susanne Dam Nielsen, MD, DMSc
Odense University Hospital; Aarhus University Hospital; Technical University...

Recruiting

Herpes Virus Infections in Kidney Transplant Patients (HINT)

Varicella Zoster Virus Infection | Vaccine-Preventable Diseases | Kidney Transplant; Complications

Denmark
Prof Patrice Lalive

Recruiting

Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients (MSHINGVAX)

Zoster | Shingles

Switzerland
Loyola University

Not yet recruiting

Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Shingles
GlaxoSmithKline

Recruiting

A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

Herpes Zoster

Italy, Spain, United Kingdom, France
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India

Herpes Zoster

India
University of Rochester
GlaxoSmithKline

Completed

Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

Chronic Lymphocytic Leukemia (CLL) | Waldenstrom Macroglobulinemia (WM)

United States
GlaxoSmithKline

Active, not recruiting

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles

Herpes Zoster

Spain, Panama, Mexico, Russian Federation, Finland, Estonia, Hong Kong, United Kingdom
Emory University

Terminated

Solid Organ Transplant SHINGRIX

Kidney Transplant; Complications

United States
Kevin Winthrop
Bristol-Myers Squibb; University of Alabama at Birmingham

Active, not recruiting

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept (BMS-188667)

Rheumatoid Arthritis | Herpes Zoster | Inflammatory Disease

United States
GlaxoSmithKline

Active, not recruiting

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

Herpes Zoster

United States, Australia, Finland, Germany, Japan, Taiwan, Sweden, Spain, Korea, Republic of, Brazil, Mexico, Italy, Canada, Czechia, Estonia, France, Hong Kong, United Kingdom
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Systems Biology of Zoster Vaccine

Zoster | Zoster Varicella | Shingles | Chicken Pox

United States
University of California, Davis
University of California, Irvine

Completed

Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer (CLOVER)

Obesity | Hepatitis C | Lung Cancer | Pneumonia, Bacterial | Tobacco Use Cessation | Colon Cancer | Shingles

United States
Immorna Biotherapeutics, Inc.
ICON plc

Active, not recruiting

A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine (JCXH-105)

Infectious Disease | Shingles | Herpes Zoster (HZ)

United States
Curevo Inc
Green Cross Corporation; Mogam Biotechnology Research Institute

Active, not recruiting

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

Herpes Zoster | Shingles

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Safety and Tolerability | Compare SHINGRIX Vaccine Response Rates

United States
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

Herpes Zoster

United States
Dynavax Technologies Corporation

Completed

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

Herpes Zoster | Vaccine-Preventable Diseases | Shingles

Australia
Merck Sharp & Dohme LLC
Kaiser Permanente

Completed

ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)

Herpes Zoster | Shingles
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

Herpes Zoster

United States, Germany, Estonia, Canada
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox

HIV Infections | Chickenpox

United States
University of Colorado, Denver
Merck Sharp & Dohme LLC; National Institute on Aging (NIA)

Completed

Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents

Immunosenescence | Shingles

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

Herpes Zoster | Herpes Zoster Vaccine

Canada, Spain, Korea, Republic of, United Kingdom, France, Czechia
Curevo Inc
Green Cross Corporation; IDRI; Mogam Biotechnology Research Institute

Completed

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

Herpes Zoster | Varicella Zoster

United States
University of Colorado, Denver
GlaxoSmithKline

Completed

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

Herpes Zoster | Shingles

United States
GlaxoSmithKline

Completed

A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022

Herpes Zoster

United States, Australia, Germany, Spain, Japan, Taiwan, Sweden, Korea, Republic of, Hong Kong, Mexico, Canada, France, Italy, Brazil, Estonia, United Kingdom, Czechia, Finland
University of Washington
Merck Sharp & Dohme LLC

Completed

Immune Response to Shingles Vaccination

Shingles

United States
GlaxoSmithKline

Completed

Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

Herpes Zoster

United States
Auburn University
Merck Sharp & Dohme LLC; Keck Graduate Institute of Claremont, California

Completed

Enhancing a Sustainable Pharmacy-based Immunization Program in Two States

Pneumococcal Infections | Herpes Zoster

United States
GlaxoSmithKline

Completed

Month 30 & 42 Extension Studies of CRD-004 Primary Study

Herpes Zoster

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

Herpes Zoster

United States, Spain, Czechia
GlaxoSmithKline

Completed

Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects

Herpes Zoster

Germany, Czechia, Sweden, Netherlands
Ohio State University

Completed

Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates

Herpes Zoster Disease

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)

Herpes Zoster
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)

Herpes Zoster | Shingles
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

Herpes Zoster

United States
Louis Stokes VA Medical Center
Duke University

Unknown

ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors

Shingles
National Institute of Allergy and Infectious Diseases...

Completed

Immune Response to Varicella-Zoster Vaccination and Infection

Herpes Zoster | Chickenpox

United States
Seoul National University Hospital

Completed

Optimal Timing of Zoster Vaccine After Zoster Illness

Shingles

Korea, Republic of
Innovaderm Research Inc.
Merck Sharp & Dohme LLC

Terminated

Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy

Psoriasis

Canada
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)

Herpes Zoster | Shingles
Merck Sharp & Dohme LLC

Completed

ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)

Herpes Zoster | Shingles
Merck Sharp & Dohme LLC
University of Colorado, Denver; Duke University

Completed

Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)

Herpes Zoster | Varicella-zoster Vaccine
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

Shingles
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)

Shingles
National Institute of Allergy and Infectious Diseases...

Completed

ZOSTAVAX® in Renal Transplant Patients

Herpes Zoster

United States
University of Toronto
Canadian Institutes of Health Research (CIHR); University of Nairobi; Kenyan...

Unknown

Pilot Study to Describe Immune Responses of Healthy Women Following Immunization With Varicella Zoster Virus Vaccine (KAVI-VZV-001)

Healthy

Kenya
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly

Shingles

United States

Search clinical trials for: Shingles vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations